Waldencast plc Files Form 25 to Voluntary Delist from Nasdaq and Deregister its Securities under the Exchange Act

Waldencast plc, parent company of Milk Makeup, has filed a Form 25 with the SEC to voluntarily delist its Class A Ordinary Shares and Warrants from Nasdaq, with delisting expected to become effective on or about October 4, 2026. The company also intends to file a Form 15 to suspend its SEC reporting obligations. The delisting is expected to result in cost savings for the company.

09/24/2026, 4:35 PM • GlobeNewswire

Waldencast plc Announces Intention to Voluntarily Delist from Nasdaq and Deregister its Securities under the Exchange Act

Waldencast plc announced its decision to voluntarily delist from Nasdaq and deregister its securities under the Exchange Act, with the last trading day expected on October 2, 2026. Following the sale of Obagi Medical, the company will become a single-brand entity focused on Milk Makeup and plans to rename itself Milk Makeup plc. The delisting is driven by disproportionate compliance costs, limited trading volume, and the company's reduced need for public equity market access after debt paydown.

09/14/2026, 6:55 AM • GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALD

Pomerantz LLP is investigating potential securities fraud claims against Waldencast plc following the company's November 24, 2025 announcement of significantly reduced financial guidance and substantial impairment charges. Waldencast downgraded its 2025 net revenue growth expectations from mid-teens to flat compared to 2024, and reduced adjusted EBITDA margin guidance from mid-to-high teens to high single digits. The company reported a $185.2 million net loss for H1 2025, including $132.1 million in impairment charges on its Obagi Medical brand and $20 million on Milk Makeup. The stock fell 6.49% on the announcement.

12/30/2025, 3:52 PM • GlobeNewswire

Obagi Medical Shares New Clinical Data on Obagi Hyaluronic Acid Injectables and Nu-Cil Scalp Serum at the 2025 American Society for Dermatologic Surgery Annual Meeting

Obagi Medical presented new clinical research at the 2025 American Society for Dermatologic Surgery Annual Meeting, highlighting pivotal studies on hyaluronic acid fillers and a scalp serum, demonstrating promising results in midface augmentation and scalp health.

11/16/2025, 1:02 AM • GlobeNewswire

Obagi Medical Launches Nu-Cil® BioStim™ Scalp Serum

Obagi Medical introduces a new scalp serum clinically proven to reduce hair loss and promote fuller hair, targeting individuals experiencing hair thinning through a scientifically formulated product.

10/08/2025, 8:00 AM • GlobeNewswire

Waldencast Announces Strong Progress on Business Priorities for H1 2025 and Initiatives to Drive Transformation

Waldencast reported mixed performance in H1 2025, with Obagi Medical and Milk Makeup experiencing growth challenges. The company acquired Novaestiq Corp., expanded into aesthetics, and initiated a strategic review to maximize shareholder value while adjusting full-year revenue and EBITDA guidance.

08/18/2025, 5:43 PM • GlobeNewswire

Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injectable Hyaluronic Acid Gel Line, Saypha®, Under the Obagi Medical Brand

Waldencast has acquired Novaestiq Corp. and the U.S. rights to the Saypha® injectable hyaluronic acid gel line, expanding Obagi Medical's portfolio into dermal fillers and positioning the company at the intersection of skincare and aesthetic treatments.

07/23/2025, 6:45 AM • Benzinga